Prima BioMed Announces New IP for Its Lead IMP321 Development Program
May 29, 2015 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - May 29, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company"), a leading immuno-oncology company, today announced that it has made...
Prima BioMed to Commercialise CVac's Database Management Platform With Database Integrations Inc. (DBI)
May 27, 2015 10:24 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - May 27, 2015) - Editors and readers are advised to disregard the duplicate news release with the headline, "CVac Shows Clear Trend for Overall Survival Benefit in...
CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study
May 26, 2015 07:50 ET
|
Prima Biomed
SYDNEY, AUSTRALIA--(Marketwired - May 26, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Final Data from the CAN-003 Phase II trial after 5 years of data...
CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study
May 19, 2015 10:19 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - May 19, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Final Data from the CAN-003 Phase II trial after 5 years of data...
Prima BioMed Announces A$15 Million Investment From US Healthcare Investor Ridgeback
May 14, 2015 06:45 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - May 14, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Highlights:
Agreement reached with Ridgeback Capital Investments, a...
Prima BioMed Announces Japanese Collaboration
May 11, 2015 07:45 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - May 11, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") announces a collaboration with NEC Corporation and Yamaguchi University for...
Prima Biomed to Prioritize Immuno-Oncology Programs Targeting Immune Checkpoint LAG-3
March 02, 2015 07:05 ET
|
Prima Biomed
SYDNEY, AUSTRALIA--(Marketwired - Mar 2, 2015) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR)
Highlights
Prima to focus on developing its highly prospective...
Prima BioMed to Receive Financial Milestone Payment From GSK
January 28, 2015 12:01 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Jan 28, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company") announces the first dosing of a subject by GSK in a Phase 1, first-in-human...
Prima BioMed Receives $777K R&D Tax Incentive Refund
January 20, 2015 08:53 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 20, 2015) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima") is pleased to advise that it has received approximately $777k in a cash rebate from the...
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
December 29, 2014 07:05 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 29, 2014) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"), announces that it received a notice, dated December 23, 2014 (the "Notice"),...